Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation
详细信息 查看全文
- 作者：Fabian Bock1 ; 2 ; Gary Lu3 ; Samer A. Srour1 ; Sameh Gaballa1 ; Heather Y. Lin4 ; Veerabhadran Baladandayuthapani4 ; Medhavi Honhar1 ; Maximilian Stich1 ; Nina Das Shah1 ; Qaiser Bashir1 ; Krina Patel1 ; Uday Popat1 ; Chitra Hosing1 ; Martin Korbling1 ; Ruby Delgado1 ; Gabriela Rondon1 ; Jatin J. Shah3 ; Sheeba K. Thomas5 ; Elisabet E. Manasanch1 ; Berend Isermann2 ; Robert Z. Orlowski3 ; Richard E. Champlin1 ; Muzaffar H. Qazilbash1 ; mqazilba@mdanderson.org" class="auth_mail" title="E-mail the corresponding author
- 关键词：CKS1B ; 1q21 ; Multiple myeloma ; Stem cell transplantation
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：22
- 期：12
- 页码：2159-2164
- 全文大小：431 K
文摘
- •
CKS1B amplification is an independent adverse prognostic factor for patients with multiple myeloma who underwent an autologous hematopoietic stem cell transplantation
- •
Progression-free survival after autologous hematopoietic stem cell transplantation for multiple myeloma patients receiving an autologous hematopoietic stem cell transplantation with CKS1B amplification is 15 months
- •
Even with a proteasome inhibitor or an immunomodulatory drug-based induction and the use of post-transplantation maintenance therapy, patients with CKS1B amplification have poor outcome